Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges
Transthyretin amyloid cardiomyopathy (ATTR-CM) is potentially a fatal disease characterized by abnormal buildup of amyloid fibrils primarily in the heart causing progressive heart failure. It is categorized into two subtypes-hereditary ATTR and wild type ATTR. Previously, no treatment is available,...
Saved in:
Main Authors: | Sweety Sharma (Author), Bhawna Sharma (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
by: Marianna Fontana, et al.
Published: (2023) -
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
by: Paolo Morfino, et al.
Published: (2023) -
A Case of Early Hereditary Transthyretin Amyloid Cardiomyopathy Recognition With Genetic Screening: A Case Report
by: Michel Juarez, et al.
Published: (2022) -
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
by: Dulce Brito (Chair), et al.
Published: (2023) -
The Structural Understanding of Transthyretin Misfolding and the Inspired Drug Approaches for the Treatment of Heart Failure Associated With Transthyretin Amyloidosis
by: Shan He, et al.
Published: (2021)